Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseChristine H. Chung, Thomas A.E. Platts‐Mills, Beloo Mirakhur et al.|New England Journal of Medicine|2008Cited by 1.5k
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Hope S. Rugo, Scot Ebbinghaus et al.|Breast Cancer Research and Treatment|2017Cited by 18
Phase II study of cetuximab in mucinous peritoneal carcinomatosisEleni Andreopoulou, Andrew M. Lowy, Franco M. Muggia et al.|Journal of Clinical Oncology|2006Cited by 4
Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancerJosé Baselga, HS Rugo, Serafín Morales et al.|Cancer Research|2013Cited by 3
Cetuximab in mucinous peritoneal carcinomatosis: Assessment by serial CA19.9 and CEA measurementsEleni Andreopoulou, Franco M. Muggia, Andrew M. Lowy et al.|Unknown|2007Cited by 0